이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Li-Fraumeni 증후군의 임상 및 유전학적 연구

2026년 11월 10일 업데이트: National Cancer Institute (NCI)

Li-Fraumeni 증후군의 임상, 역학 및 유전학적 연구

Background:

- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may increase or decrease cancer risk in people with the syndrome.

Objectives:

  • To learn more about the types of cancers that occur in individuals with LFS.
  • To study the role of the TP53 gene in the development of cancer.
  • To look for other possible genes that cause LFS
  • To study the effect of LFS diagnosis on families.
  • To determine if environmental factors or other genes can change a person s cancer risk associated with LFS.

Eligibility:

  • Individuals with a family or personal medical history of cancers consistent with LFS.
  • Individuals with a family or personal medical history of cancers that does not meet the diagnosis of LFS, but the history is suggestive for LFS (meets the diagnosis for the so-called Li-Fraumeni like syndrome)
  • Individuals with certain rare cancers
  • Individuals with a family or personal history of a TP53 gene mutation, with or without related cancer(s).

Design:

  • Participants will fill out a medical history questionnaire and a family history questionnaire.
  • Blood samples will be collected for DNA and for storage. Cheek cell samples may be collected if blood cannot be obtained for DNA. Participants can choose to have or not have cancer screening with blood tests, imaging studies, and other exams.
  • Participants will complete questionnaires about their worries about cancer, stress levels, and coping strategies. Diet and physical activity questionnaires will also be given. Other psychological tests may be given as needed.
  • Participants will be monitored for several years, with regular followup visits to the National Institutes of Health, if indicated. Any changes in health or cancer status will be recorded.

연구 개요

상태

모병

정황

상세 설명

Study Description:

This is a natural history study involving questionnaires, clinical and research evaluations, clinical and research laboratory tests, review of

medical records, and cancer surveillance. This is a prospective long-term study of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) or Li-Fraumeni-Like Syndrome (LFL), using a cohort approach. Enrollees are invited to participate in all aspects of the study but can choose to opt out of specific part(s).

Objectives:

Primary Objectives:

  • To ascertain/enroll individuals and families with Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-Like Syndrome (LFL)
  • To evaluation and define the clinical spectrum and natural history of disease in LFS and LFL
  • To quantify cumulative cancer risk in individuals with LFS or LFL
  • To develop a cancer screening program for individuals with LFS or LFL
  • To investigate the mechanisms of tumorigenesis in LFS-related tumors (e.g., cell proliferation, growth regulation, apoptosis)
  • To identify genetic determinants, environmental factors, and gene-environment interactions that potentially modify cancer risk in

these high-risk individuals

  • To evaluate the psychological, behavioral, and social functioning effects of LFS on affected individuals and their family members
  • To explore the plausibility of lifestyle interventions as potential strategies for cancer risk reduction
  • To create an annotated biospecimen repository of LFS-related for translational, etiologic, and outcomes research

Secondary Objectives:

-To evaluate specific tumor characteristics, including histologies (e.g., leukemia types, brain tumor types, etc.) of cancers

diagnosed in individuals with LFS or LFL.

-To evaluate the potential effect of therapeutic radiation and radiation exposure from diagnostic/screening imaging studies on

cancer risk.

  • To provide education, cancer risk assessment, and risk management recommendations for study participants.
  • To collect clinical data related to the treatment of LFS-related cancers, so that outcome and survival may be evaluated.

Endpoints: Primary Endpoint:

-Occurrence of cancer in individuals and families with LFS or LFL

연구 유형

관찰

등록 (추정된)

5000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Institutes of Health Clinical Center
        • 연락하다:
          • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
          • 전화번호: 888-624-1937
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Cancer Institute - Shady Grove
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Eligibility for the LFS study population: - A family or personal medical history of cancers consistent with the diagnosis of LFS or LFL; or, - A personal history of a germline TP53 mutation; or, - A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or, - A personal history of three or more LFS-related primary cancers; or, - A personal history of adrenal cortical carcinoma or choroid plexus carcinoma at any age

설명

  • INCLUSION CRITERIA:
  • On referral, persons of all ages will be considered for inclusion in the study

because of either:

  • A family or personal medical history of neoplasia consistent with the diagnosis of LFS or LFL; or,
  • A personal history of a germline TP53 mutation; or,
  • A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or,
  • A personal history of three or more LFS-related primary cancers; or,
  • A personal history of adrenal cortical carcinoma or choroid plexus carcinoma at any age, regardless of family history

Personal and family medical history must be verified through questionnaires, interviews, review

of medical records and/or review of pathology slides.

There are 72 families who have previously enrolled in the pilot study under protocol 78-C-0039.

As the eligibility criteria remain the same, these families will be eligible for this protocol and will be invited to sign the new consent.

-Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.

For both the Field and Clinical Center Cohort, the PI will ensure that study investigators will

identify an appropriate LAR consistent with requirements of Policy 403 and will obtain consent

from the LAR as outlined in the consent process before initiating research interventions.

-Pregnant women

In order to study the lifetime rates of cancer development in all individuals with Li-Fraumeni

syndrome, we will need to evaluate what effect pregnancy may have on rate of cancer

development both in affected individuals and unaffected family controls. Additionally, some

cancers are known to have an increased risk of development in the context of pregnancy and

lactation. Exclusion of pregnant women would preclude understanding of these cancer risks for

an important subset of the population.

Pregnant women are eligible for enrollment on the data collection component of this study.

Pregnant women will be included in this study as several endpoints may be assessed during

pregnancy; counseling, education, and other minimal risk procedures (i.e. blood draw) may be

done. We will postpone full clinical evaluations at the Clinical Center of pregnant women until

the subject has recovered post-partum.

All screening studies, for women who are pregnant, or breastfeeding will be deferred while the

woman is pregnant or breastfeeding. Pregnancy testing will be performed for females of childbearing age prior to imaging studies, and the test results must be negative prior to the scan..

The risk to the fetus and pregnant woman would be no greater than minimal for procedures that

are performed.

EXCLUSION CRITERIA:

  • Referred individuals and families whose reported diagnoses cannot be verified
  • Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would preclude the ability to participate in clinical research
  • Women who are pregnant will not be eligible for the cancer screening protocol until they recover post-partum. Women participating in the cancer screening protocol will discontinue this component if they become pregnant while on study. Once they recover post-partum, they can continue the cancer screening protocol.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: FAMILY_BASED
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
1

Patients within a family with a known TP53 mutation who are positive for that mutation.

2

Patients within a family with a known TP53 mutation who are negative for that mutation.

3

Unaffected family members.

4

Patients who meet clinical LFS criteria but haven't had TP53 testing.

5

Patients within a family with an negative/unknown TP53 mutation.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Prevalence
기간: ongoing

Learn more about the types of cancers that occur in individuals with LFS and the age at which these cancers are usually found

ongoing
Multiple measures
기간: ongoing

Explore ways to lower cancer risk

ongoing
Multiple measures
기간: ongoing

Explore the typical features of the cancers diagnosed in individuals with LFS

ongoing
Multiple measures
기간: ongoing

Explore the psychological and social functioning issues faced by LFS families

ongoing
Multiple measures
기간: ongoing

Explore the best ways to look for cancers early in individuals with LFS

ongoing
Multiple measures
기간: ongoing

Determine if there is any connection between specific mutations in the TP53 gene and the risk of certain type of cancers

ongoing
Multiple measures
기간: ongoing

Determine if there are any environmental factors or other genes that can change a person's cancer risk associated with LFS

ongoing
Multiple measures
기간: ongoing

Determine how often a change (mutation) in the TP53 gene is found in families in which LFS is suspected

ongoing

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Payal P Khincha, M.D., National Cancer Institute (NCI)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2012년 1월 17일

연구 등록 날짜

최초 제출

2011년 9월 28일

QC 기준을 충족하는 최초 제출

2011년 9월 28일

처음 게시됨 (추정된)

2011년 9월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 10월 16일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 110255
  • 11-C-0255

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .